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BACKGROUND
The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when 
added to standard care in patients with type 2 diabetes, remains unknown.
METHODS
In this double-blind trial, we randomly assigned patients with type 2 diabetes and 
high cardiovascular risk to receive liraglutide or placebo. The primary composite 
outcome in the time-to-event analysis was the first occurrence of death from car-
diovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The pri-
mary hypothesis was that liraglutide would be noninferior to placebo with regard 
to the primary outcome, with a margin of 1.30 for the upper boundary of the 95% 
confidence interval of the hazard ratio. No adjustments for multiplicity were per-
formed for the prespecified exploratory outcomes.
RESULTS
A total of 9340 patients underwent randomization. The median follow-up was 
3.8 years. The primary outcome occurred in significantly fewer patients in the 
liraglutide group (608 of 4668 patients [13.0%]) than in the placebo group (694 of 
4672 [14.9%]) (hazard ratio, 0.87; 95% confidence interval [CI], 0.78 to 0.97; 
P<0.001 for noninferiority; P = 0.01 for superiority). Fewer patients died from cardio-
vascular causes in the liraglutide group (219 patients [4.7%]) than in the placebo 
group (278 [6.0%]) (hazard ratio, 0.78; 95% CI, 0.66 to 0.93; P = 0.007). The rate of 
death from any cause was lower in the liraglutide group (381 patients [8.2%]) than 
in the placebo group (447 [9.6%]) (hazard ratio, 0.85; 95% CI, 0.74 to 0.97; P = 0.02). 
The rates of nonfatal myocardial infarction, nonfatal stroke, and hospitalization for 
heart failure were nonsignificantly lower in the liraglutide group than in the pla-
cebo group. The most common adverse events leading to the discontinuation of 
liraglutide were gastrointestinal events. The incidence of pancreatitis was non-
significantly lower in the liraglutide group than in the placebo group.
CONCLUSIONS
In the time-to-event analysis, the rate of the first occurrence of death from car-
diovascular causes, nonfatal myocardial infarction, or nonfatal stroke among 
patients with type 2 diabetes mellitus was lower with liraglutide than with pla-
cebo. (Funded by Novo Nordisk and the National Institutes of Health; LEADER 
ClinicalTrials.gov number, NCT01179048.)
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T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Type 2 diabetes is a complex metabolic disorder that is characterized by hypergly-cemia and associated with a high risk of 
cardiovascular, microvascular, and other compli-
cations.1,2 Although glycemic control is associated 
with reductions in the risk of microvascular com-
plications, the macrovascular benefits of glyce-
mic control are less certain. Furthermore, con-
cern has been raised about the cardiovascular 
safety of antihyperglycemic therapies.3 Conse-
quently, regulatory authorities have mandated 
cardiovascular safety assessments of new diabe-
tes treatments.4,5
Liraglutide, an analogue of human glucagon-
like peptide 1 (GLP-1),6 has been approved for 
the treatment of type 2 diabetes. Its efficacy in 
lowering glucose levels has been established, 
and it has been associated with slight reductions 
in weight and blood pressure.6-8 It has been asso-
ciated with an increase in pulse rate.7,8 To assess 
the long-term effects of liraglutide on cardio-
vascular outcomes and other clinically impor-
tant events, the Liraglutide Effect and Action in 
Diabetes: Evaluation of Cardiovascular Outcome 
Results (LEADER) trial was initiated in 2010.9
Me thods
Trial Design and Oversight
We performed this multicenter, double-blind, 
placebo-controlled trial at 410 sites in 32 coun-
tries. Detailed methods of the trial have been 
published previously,9 and the trial protocol is 
available with the full text of this article at 
NEJM.org. The trial protocol was reviewed and 
approved by the institutional review board or 
ethics committee at each participating center. 
All the patients provided written informed con-
sent before participation. Patients with type 2 
diabetes who were at high risk for cardiovascu-
lar disease were randomly assigned, in a 1:1 ratio, 
to receive liraglutide or placebo. The minimum 
planned follow-up was 42 months, with a maxi-
mum of 60 months of receiving the assigned 
regimen and an additional 30 days of follow-up 
afterward.
The trial was overseen by a steering commit-
tee consisting of 11 academic investigators and 
4 employees of the sponsor. The steering com-
mittee, in collaboration with the sponsor and 
regulatory authorities, was responsible for de-
signing the trial protocol. An independent data 
and safety monitoring committee performed on-
going safety surveillance and had access to all 
the data in an unblinded fashion. The protocol 
for the treatment of risk factors and the con-
comitant use of medications was developed by a 
global expert panel (Table S1 in the Supplemen-
tary Appendix, available at NEJM.org). The data 
were gathered by the site investigators, and the 
sponsor performed site monitoring and data col-
lection. The data were analyzed by Statogen 
Consulting and the sponsor.
All the authors had access to the final results 
and vouch for the fidelity of the trial to the pro-
tocol. The first and last authors wrote the first 
draft of the manuscript, which was revised and 
approved by all the authors, who also assume 
responsibility for the accuracy and completeness 
of its content and for the decision to submit the 
manuscript for publication. Editorial support, 
funded by the sponsor, was provided by an inde-
pendent medical writer under the guidance of 
the authors.
Patients
Patients with type 2 diabetes who had a glycated 
hemoglobin level of 7.0% or more were eligible 
if they either had not received drugs for this 
condition previously or had been treated with 
one or more oral antihyperglycemic agents or 
insulin (human neutral protamine Hagedorn, 
long-acting analogue, or premixed) or a combina-
tion of these agents. The major inclusion criteria 
were the following: an age of 50 years or more 
with at least one cardiovascular coexisting con-
dition (coronary heart disease, cerebrovascular 
disease, peripheral vascular disease, chronic kid-
ney disease of stage 3 or greater, or chronic heart 
failure of New York Heart Association class II or 
III) or an age of 60 years or more with at least 
one cardiovascular risk factor, as determined by 
the investigator (microalbuminuria or protein-
uria, hypertension and left ventricular hypertro-
phy, left ventricular systolic or diastolic dysfunc-
tion, or an ankle–brachial index [the ratio of the 
systolic blood pressure at the ankle to the sys-
tolic blood pressure in the arm] of less than 
0.9).9 Major exclusion criteria were type 1 diabe-
tes; the use of GLP-1–receptor agonists, dipep-
tidyl peptidase 4 (DPP-4) inhibitors, pramlintide, 
or rapid-acting insulin; a familial or personal 
history of multiple endocrine neoplasia type 2 or 
medullary thyroid cancer; and the occurrence of 
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an acute coronary or cerebrovascular event with-
in 14 days before screening and randomization. 
The complete inclusion and exclusion criteria are 
listed in the Supplementary Appendix.
Procedures
After a 2-week placebo run-in phase to establish 
whether patients were able to adhere to the injec-
tion regimen, patients were randomly assigned, 
in a 1:1 ratio, to receive either 1.8 mg (or the 
maximum tolerated dose) of liraglutide or match-
ing placebo once daily as a subcutaneous injec-
tion in addition to standard care (Fig. S1 in the 
Supplementary Appendix). Randomization was 
stratified according to the estimated glomerular 
filtration rate (eGFR) at screening (<30 or ≥30 
ml per minute per 1.73 m2 of body-surface area), 
as calculated with the use of the Modification of 
Diet in Renal Disease equation. For patients who 
did not meet the recommended target for glyce-
mic control (glycated hemoglobin level ≤7% or 
individualized target at the investigator’s discre-
tion) after randomization, the addition of any 
antihyperglycemic agents except for GLP-1– 
receptor agonists, DPP-4 inhibitors, or pramlin-
tide was permitted. Patients were scheduled for 
follow-up visits at months 1, 3, and 6 and every 
6 months thereafter.
Outcomes
The primary composite outcome in the time-to-
event analysis was the first occurrence of death 
from cardiovascular causes, nonfatal (including 
silent) myocardial infarction, or nonfatal stroke. 
Prespecified exploratory outcomes included an 
expanded composite cardiovascular outcome 
(death from cardiovascular causes, nonfatal myo-
cardial infarction, nonfatal stroke, coronary re-
vascularization, or hospitalization for unstable 
angina pectoris or heart failure), death from any 
cause, a composite renal and retinal microvascu-
lar outcome (nephropathy [defined as the new 
onset of macroalbuminuria or a doubling of the 
serum creatinine level and an eGFR of ≤45 ml 
per minute per 1.73 m2, the need for continuous 
renal-replacement therapy, or death from renal 
disease] and retinopathy [defined as the need for 
retinal photocoagulation or treatment with intra-
vitreal agents, vitreous hemorrhage, or the onset 
of diabetes-related blindness]), neoplasms, and 
pancreatitis — all of which were adjudicated in 
a blinded fashion by an external, independent 
event-adjudication committee. The definitions 
that were used for the clinical events and the 
members of the committee are listed in the 
Supplementary Appendix.
The glycated hemoglobin level was measured 
at randomization, at month 3, and then every 
6 months thereafter. Other laboratory tests were 
performed at randomization, at months 6 and 12, 
and annually thereafter. Prespecified comparisons 
between groups were performed at 36 months, 
which was the last annual visit with laboratory 
testing that was prespecified for the entire trial 
population, given the minimum follow-up of 
42 months.
Statistical Analysis
The statistical analysis plan is available with the 
protocol at NEJM.org. We based the required 
sample size for the trial on an assumed annual 
primary-event rate of 1.8% in each group. Uni-
form enrollment was projected over the period 
of 1.5 years. Assuming a withdrawal rate of less 
than 10%, a minimum exposure to the trial 
regimen of 42 months, a null hypothesis hazard 
ratio of 1.30 or more, 90% power, and a one-
sided alpha level of 0.025, we calculated that 
8754 patients would need to undergo randomiza-
tion if we were to observe at least 611 primary 
outcomes.
The primary and exploratory analyses for the 
outcomes in the time-to-event analyses were 
based on a Cox proportional-hazards model with 
treatment as a covariate. The primary hypothesis 
was that liraglutide would be noninferior to pla-
cebo with regard to the primary outcome, with 
a margin of 1.30 for the upper boundary of the 
95% confidence interval of the hazard ratio. We 
used a hierarchical testing strategy for the lira-
glutide group versus the placebo group, first 
testing for noninferiority and subsequently for 
superiority. Noninferiority was established for 
the primary outcome if the upper limit of the 
two-sided 95% confidence interval of the hazard 
ratio was less than 1.30, and superiority was 
established if the upper limit was less than 1.00. 
In addition, prespecified sensitivity analyses were 
conducted (see the protocol). For exploratory 
outcomes, no adjustments of P values for multi-
plicity were performed. All the patients who 
underwent randomization were included in the 
primary and exploratory analyses, and data from 
the patients who completed or discontinued the 
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trial without having an outcome were censored 
from the day of their last visit; events occurring 
after that visit were not included. Two-sided 
P values are presented throughout. We estimated 
the mean differences between the trial groups in 
the glycated hemoglobin level, weight, systolic 
and diastolic blood pressure, and pulse using a 
mixed model for repeated measurements, with 
adjustment for baseline covariates.
R esult s
Overview of Trial Conduct
A total of 9340 patients underwent randomiza-
tion from September 2010 through April 2012; 
4668 patients were randomly assigned to receive 
liraglutide and 4672 to receive placebo. The 
planned closeout of follow-up of the patients 
was from August 2014 through December 2015. 
The vital status was known in 99.7% of the pa-
tients. A total of 96.8% of the patients com-
pleted a final visit, died, or had a primary out-
come. The median time of exposure to liraglutide 
or placebo was 3.5 years. The mean percentage 
of time that patients received the trial regimen 
was 84% for liraglutide and 83% for placebo. 
The median follow-up was 3.8 years in each 
group. The median daily dose of liraglutide was 
1.78 mg (interquartile range, 1.54 to 1.79), includ-
ing periods during which the patients did not 
receive liraglutide. The screening, randomization, 
and follow-up of the patients are shown in Fig-
ure S2 in the Supplementary Appendix.
The demographic and clinical characteristics 
of the patients were similar in the two groups 
(Table S2 in the Supplementary Appendix). Of 
the 9340 patients, the majority (7598 [81.3%]) 
had established cardiovascular disease (6764 pa-
tients [72.4%]), chronic kidney disease of stage 3 
or higher (2307 [24.7%]), or both (1473 [15.8%]). 
At baseline, the mean duration of diabetes was 
12.8 years, and the mean glycated hemoglobin 
level was 8.7%.
Cardiovascular Outcomes
The composite primary outcome occurred in 
fewer patients in the liraglutide group (608 of 
4668 patients [13.0%]) than in the placebo group 
(694 of 4672 [14.9%]) (hazard ratio, 0.87; 95% 
confidence interval [CI], 0.78 to 0.97; P<0.001 for 
noninferiority; P = 0.01 for superiority) (Table 1 
and Fig. 1A). Death from cardiovascular causes 
occurred in fewer patients in the liraglutide 
group (219 patients [4.7%]) than in the placebo 
group (278 [6.0%]) (hazard ratio, 0.78; 95% CI, 
0.66 to 0.93; P = 0.007) (Fig. 1B). The rate of 
death from any cause was also lower in the lira-
glutide group (381 patients [8.2%]) than in the 
placebo group (447 [9.6%]) (hazard ratio, 0.85; 
95% CI, 0.74 to 0.97; P = 0.02). The frequencies 
of nonfatal myocardial infarction and nonfatal 
stroke were lower in the liraglutide group than 
in the placebo group, although the differences 
were not significant (Fig. 1C and 1D and Table 1). 
The magnitude of the differences was similar in 
sensitivity analyses with alternative censoring, 
including the per-protocol analysis (Fig. S3 in 
the Supplementary Appendix). Findings for the 
remaining adjudicated cardiovascular outcomes 
and the expanded composite outcome are pro-
vided in Table 1, and Figure S4 in the Supple-
mentary Appendix.
Subgroup analyses are shown in Figure 2. 
Significant interactions were observed for an 
eGFR of 60 ml or more per minute per 1.73 m2 
versus an eGFR of less than 60 ml per minute 
per 1.73 m2, with a benefit favoring the lower 
eGFR, and for the presence versus absence of 
established cardiovascular disease at baseline, 
with benefit for those with cardiovascular dis-
ease at baseline. Additional subgroup analyses 
regarding the eGFR are provided in Table S3 in 
the Supplementary Appendix.
Glycemic Control
Changes in the glycated hemoglobin values over 
time are shown in Figure S5A in the Supplemen-
tary Appendix. The prespecified analysis at 36 
months showed a mean difference between the 
liraglutide group and the placebo group of −0.40 
percentage points (95% CI, −0.45 to −0.34). 
Changes in the use of diabetes medication dur-
ing the trial are shown in Table S4 in the Supple-
mentary Appendix.
Cardiovascular Risk Factors
There were significant mean differences between 
the liraglutide group and the placebo group in 
the change from baseline to 36 months in the 
following variables: weight loss was 2.3 kg (95% 
CI, 2.5 to 2.0) higher in the liraglutide group, the 
systolic blood pressure was 1.2 mm Hg (95% CI, 
1.9 to 0.5) lower in the liraglutide group, the dia-
stolic blood pressure was 0.6 mm Hg (95% CI, 
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0.2 to 1.0) higher in the liraglutide group, and 
the heart rate was 3.0 beats per minute (95% CI, 
2.5 to 3.4) higher in the liraglutide group (Fig. 
S5B, S5C, and S5D in the Supplementary Appen-
dix). The use of cardiovascular medications at 
baseline and during the trial is shown in Table 
S4 in the Supplementary Appendix.
Microvascular Outcomes
The incidence of a composite outcome of renal 
or retinal microvascular events was lower in the 
liraglutide group than in the placebo group 
(hazard ratio, 0.84; 95% CI, 0.73 to 0.97; P = 0.02), 
a difference that was driven by a lower rate of 
nephropathy events in the liraglutide group (1.5 
vs. 1.9 events per 100 patient-years of observa-
tion; hazard ratio, 0.78; 95% CI, 0.67 to 0.92; 
P = 0.003) (Table 1). The incidence of retinopathy 
events was nonsignificantly higher in the lira-
glutide group than in the placebo group (0.6 vs. 
0.5 events per 100 patient-years; hazard ratio, 
1.15; 95% CI, 0.87 to 1.52; P = 0.33).
Safety and Adverse Events
Adverse events are listed in Table 2. The overall 
rates of benign or malignant neoplasms were 
higher in the liraglutide group than in the pla-
cebo group, but the difference was not signifi-
cant (Fig. S6 in the Supplementary Appendix). 
There were 13 patients with pancreatic cancer in 
the liraglutide group and 5 in the placebo group. 
Additional data regarding pancreatic cancer are 
provided in Table S5 in the Supplementary Ap-
pendix. There were fewer patients with prostate 
cancer in the liraglutide group than in the pla-
cebo group (26 vs. 47) and also fewer patients 
with leukemia (5 vs. 14) (Fig. S6 in the Supple-
mentary Appendix). Medullary thyroid carcinoma 
occurred in no patient in the liraglutide group 
and in 1 in the placebo group. Calcitonin levels 
over time were similar in the two groups (data 
not shown).
Acute pancreatitis occurred in 18 patients in 
the liraglutide group and in 23 in the placebo 
group. The mean levels of serum amylase and 
lipase were higher in the liraglutide group than 
in the placebo group (Fig. S7 in the Supplemen-
tary Appendix). Acute gallstone disease was more 
common with liraglutide than with placebo (in 
145 vs. 90 patients), including severe events (in 
40 vs. 31). During the trial, fewer patients in the 
liraglutide group were treated with hypoglycemic 
medications (insulin, sulfonylurea, and glinides) 
than in the placebo group (Table S4 in the Sup-
plementary Appendix). Severe hypoglycemia oc-
curred in 114 patients in the liraglutide group 
and in 153 in the placebo group (rate ratio, 0.69; 
95% CI, 0.51 to 0.93). Similarly, the rate ratio for 
confirmed hypoglycemia (plasma glucose level, 
<56 mg per deciliter [3.1 mmol per liter]) was 
0.80 (95% CI, 0.74 to 0.88). Additional details 
regarding severe hypoglycemia are provided in 
Table S6 in the Supplementary Appendix.
Adverse events leading to the permanent dis-
continuation of the trial regimen were more 
common with liraglutide than with placebo 
(Table 2). This result appears to have been driven 
by gastrointestinal disorders in the liraglutide 
group.
Discussion
In the present trial, patients in the liraglutide 
group had a lower risk of the primary composite 
outcome — first occurrence of cardiovascular 
death, nonfatal myocardial infarction, or non-
fatal stroke in the time-to-event analysis — and 
lower risks of death from cardiovascular causes, 
death from any cause, and microvascular events 
than did those in the placebo group. The num-
ber of patients who would need to be treated to 
prevent one event in 3 years was 66 in the analy-
sis of the primary outcome and 98 in the analysis 
of death from any cause.10 There has been con-
cern about the risk of hospitalization for heart 
failure with various agents that have been used to 
treat diabetes mellitus, including DPP-4 inhibi-
tors.11 In the present trial, there were fewer 
Figure 1 (facing page). Primary and Exploratory Outcomes.
The primary composite outcome in the time-to-event 
analysis was the first occurrence of death from cardio-
vascular causes, nonfatal myocardial infarction, or non-
fatal stroke. The cumulative incidences were estimated 
with the use of the Kaplan–Meier method, and the haz-
ard ratios with the use of the Cox proportional-hazard 
regression model. The data analyses are truncated at 
54 months, because less than 10% of the patients had 
an observation time beyond 54 months. The insets show 
the same data on an enlarged y axis.
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1.0 2.0
Placebo BetterLiraglutide Better
Primary analysis
Sex
Female
Male
Age
<60 yr
≥60 yr
Geographic region
Europe
North America
Asia
Rest of the world
Race
White
Black 
Asian
Other
Ethnic group
Hispanic
Non-Hispanic
Body-mass index
≤30
>30
Glycated hemoglobin
≤8.3%
>8.3%
Duration of diabetes
≤11 yr
>11 yr
Risk of CVD
≥50 yr of age and established CVD
≥60 yr of age and risk factors for CVD
Chronic heart failure
Yes
No
Antidiabetic therapy
1 Oral antidiabetic agent
>1 Oral antidiabetic agent
Insulin with oral antidiabetic agent
Insulin without oral antidiabetic agent
None
Renal function
Severe or moderate disease
<60 ml/min/1.73 m2
≥60 ml/min/1.73 m2
Severe disease
<30 ml/min/1.73 m2
≥30 ml/min/1.73 m2
Liraglutide Hazard Ratio (95% CI)PlaceboSubgroup
0.89 (0.74–1.06)
0.95 (0.78–1.16)
0.85 (0.76–0.96)
0.94 (0.72–1.21)
0.86 (0.63–1.17)
0.83 (0.74–0.93)
0.82 (0.70–0.97)
1.20 (0.86–1.67)
0.96 (0.81–1.15)
0.82 (0.71–0.94)
0.84 (0.72–0.98)
0.89 (0.76–1.05)
0.73 (0.42–1.25)
0.94 (0.83–1.07)
0.69 (0.57–0.85)
0.87 (0.77–0.97)
0.89 (0.51–1.54)
0.75 (0.58–0.98)
0.89 (0.79–1.00)
0.74 (0.54–1.02)
0.61 (0.37–1.00)
0.90 (0.78–1.04)
0.87 (0.59–1.27)
0.70 (0.46–1.04)
0.90 (0.80–1.02)
0.83 (0.68–1.03)
1.01 (0.84–1.22)
0.62 (0.37–1.04)
0.82 (0.68–0.98)
0.78 (0.62–0.97)
0.90 (0.79–1.02)
0.88 (0.72–1.08)
0.87 (0.78–0.97)
0.2
0.86 (0.75–0.98)
P Value for
Interaction
  608/4668 (13.0)  
183/1657 (11.0)
425/3011 (14.1)
140/1197 (11.7)
468/3471 (13.5)
207/1639 (12.6)
212/1401 (15.1)
24/360 (6.7)  
165/1268 (13.0)
494/3616 (13.7)
  47/370 (12.7)  
40/471 (8.5)  
  27/211 (12.8)  
  68/580 (11.7)  
540/4088 (13.2)
241/1743 (13.8)
367/2920 (12.6)
289/2340 (12.4)
319/2328 (13.7)
265/2216 (12.0)
340/2441 (13.9)
536/3831 (14.0)
  72/837 (8.6)    
112/653 (17.2)  
496/4015 (12.4)
  99/922 (10.7)  
191/1515 (12.6)
223/1674 (13.3)
  71/361 (19.7)  
  24/196 (12.2)  
172/1116 (15.4)
436/3552 (12.3)
  25/117 (21.4)
583/4551 (12.8)
  694/4672 (14.9)  
209/1680 (12.4)
485/2992 (16.2)
166/1124 (14.8)
528/3548 (14.9)
252/1657 (15.2)
216/1446 (14.9)
  37/351 (10.5)  
189/1218 (15.5)
543/3622 (15.0)
  59/407 (14.5)  
  56/465 (12.0)  
  36/178 (20.2)  
  86/554 (15.5)  
608/4118 (14.8)
261/1831 (14.3)
431/2837 (15.2)
333/2428 (13.7)
361/2244 (16.1)
316/2213 (14.3)
376/2451 (15.3)
629/3767 (16.7)
65/905 (7.2)  
119/652 (18.3)  
575/4020 (14.3)
125/896 (14.0)  
196/1482 (13.2)
259/1748 (14.8)
  86/376 (22.9)  
  28/170 (16.5)  
223/1042 (21.4)
471/3630 (13.0)
  26/107 (24.3)
668/4565 (14.6)
No. of
Patients
9340
3337
6003
2321
7019
3296
2847
711
2486
7238
777
936
389
1134
8206
3574
5757
4768
4572
4429
4892
7598
1742
1305
8035
1818
2997
3422
737
366
2158
7182
224
9116
0.84
0.27
0.20
0.32
0.30
0.15
0.58
0.42
0.04
0.53
0.73
0.01
0.93
no. of events/no. of patients (%)
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hospitalizations for heart failure among patients 
in the liraglutide group than among those in the 
placebo group, although the difference was not 
significant.
Sensitivity analyses suggested that our find-
ings were robust to baseline adjustment and alter-
native censoring. Cardiovascular benefits were 
observed in the context of generally acceptable 
levels of cardiovascular risk-factor management 
at baseline and during the trial. There were 
fewer add-on therapies for diabetes medications, 
lipid-lowering medications, and diuretics in 
patients in the liraglutide group than in those 
in the placebo group. Subgroup analyses suggest 
a greater benefit of liraglutide with respect to 
the primary outcome in patients with an eGFR 
of less than 60 ml per minute per 1.73 m2 and 
possibly in patients with a history of cardiovas-
cular disease. A sensitivity analysis of data for 
patients with an eGFR of less than 60 ml per 
minute per 1.73 m2 did not support a clinically 
meaningful interaction (Table S3 in the Supple-
mentary Appendix).
The pattern of cardiovascular benefits that 
were associated with liraglutide in our trial ap-
pears to differ from that with the sodium–glucose 
cotransporter 2 inhibitor empaglif lozin in the 
previously reported EMPA-REG OUTCOME trial.12 
The time to benefit emerged earlier in that trial 
than in the present trial, and the heterogeneity 
of the direction and magnitude of the effects on 
the components of the composite primary out-
come in that trial contrasts with the consistency 
of the effect in the present trial. Although these 
differences may reflect patient populations or 
chance, the observed benefits in that trial may be 
more closely linked to hemodynamic changes, 
whereas in the present trial, the observed bene-
fits are perhaps related to the modified progres-
sion of atherosclerotic vascular disease.13
It should be noted that in the Evaluation of 
Lixisenatide in Acute Coronary Syndrome (ELIXA) 
trial,14 the GLP-1–receptor agonist lixisenatide, 
which is shorter-acting than and structurally dis-
similar to liraglutide, did not show any cardio-
vascular benefit in patients with diabetes and a 
recent acute coronary syndrome. There are a 
number of other trials regarding cardiovascular 
outcomes in high-risk cohorts of patients with 
type 2 diabetes in which similar magnitude ef-
fects on glycemic control have been shown but 
without significant benefits with respect to rates 
of cardiovascular events or death.15-20 These in-
clude trials with insulin,16 thiazolidinediones,15,18 
and DPP-4 inhibitors.17,19,20 Our trial had greater 
statistical power and included patients with a 
higher baseline glycated hemoglobin level than 
did most previous studies. However, no obvious 
single explanation in terms of either the study 
designs or the included populations is apparent 
to explain the divergent findings across this body 
of medical literature.
The prespecified primary microvascular out-
come in our trial was a composite of nephropa-
thy and retinopathy outcomes. The benefit with 
liraglutide was driven by lower rates of renal 
outcomes, such as new-onset persistent macro-
albuminuria in particular. There was a higher 
rate of retinopathy events with liraglutide than 
with placebo, although the difference was not 
significant. With moderate differences in glyce-
mic control between the trial groups over a 
median 3.8 years of follow-up, the achievement 
of renal microvascular benefits is surprising. It 
is uncertain whether this finding relates to the 
Figure 2 (facing page). Primary Composite Outcomes 
in Various Demographic and Clinical Subgroups.
Prespecified Cox proportional-hazard regression analy-
ses were performed for subgroups of patients with re-
spect to the primary outcome (first occurrence of death 
from cardiovascular causes, nonfatal myocardial infarc-
tion, or nonfatal stroke). P values signify tests of homo-
geneity for between-group differences with no adjust-
ment for multiple testing. The percentages of patients 
with a first primary outcome between the randomiza-
tion date and the date of last follow-up are shown. Race 
and ethnic group were self-reported. There were miss-
ing data for the body-mass index (the weight in kilograms 
divided by the square of the height in meters) in 5 pa-
tients in the liraglutide group and 4 in the placebo group 
and for the duration of diabetes in 11 patients in the 
 liraglutide group and 8 in the placebo group. Renal 
function was assessed by means of the estimated glo-
merular filtration rate, as calculated by the Modifica-
tion of Diet in Renal Disease equation. CVD denotes 
cardiovascular disease.
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Event
Liraglutide 
(N = 4668)
Placebo 
(N = 4672) P Value
no. of patients (%)
Adverse event
Any adverse event 2909 (62.3) 2839 (60.8) 0.12
Serious adverse event 2320 (49.7) 2354 (50.4) 0.51
Confirmed hypoglycemia† 2039 (43.7) 2130 (45.6) 0.06
Severe adverse event 1502 (32.2) 1533 (32.8) 0.51
Severe hypoglycemia† 114 (2.4) 153 (3.3) 0.02
Acute gallstone disease 145 (3.1) 90 (1.9) <0.001
Cholelithiasis 68 (1.5) 50 (1.1) 0.09
Acute cholecystitis 36 (0.8) 21 (0.4) 0.046
Hypothyroidism 44 (0.9) 33 (0.7) 0.21
Hyperthyroidism 13 (0.3) 8 (0.2) 0.27
Diabetic foot ulcer 181 (3.9) 198 (4.2) 0.38
Allergic reaction 59 (1.3) 44 (0.9) 0.14
Injection-site reaction 32 (0.7) 12 (0.3) 0.002
Adverse event leading to permanent discontinuation 
of trial regimen
Any adverse event 444 (9.5) 339 (7.3) <0.001
Serious adverse event 192 (4.1) 245 (5.2) 0.01
Severe adverse event 164 (3.5) 188 (4.0) 0.20
Nausea 77 (1.6) 18 (0.4) <0.001
Vomiting 31 (0.7) 2 (<0.1) <0.001
Diarrhea 27 (0.6) 5 (0.1) <0.001
Increased lipase level‡ 15 (0.3) 11 (0.2) 0.43
Abdominal pain 11 (0.2) 3 (0.1) 0.03
Decreased appetite 11 (0.2) 2 (<0.1) 0.01
Abdominal discomfort 10 (0.2) 0 0.002
Pancreatitis or neoplasm§
Acute pancreatitis 18 (0.4) 23 (0.5) 0.44
Chronic pancreatitis 0 2 (<0.1) 0.16
Any benign neoplasm 168 (3.6) 145 (3.1) 0.18
Any malignant neoplasm 296 (6.3) 279 (6.0) 0.46
Pancreatic carcinoma 13 (0.3) 5 (0.1) 0.06
Medullary thyroid carcinoma 0 1 (<0.1) 0.32
*  Serious adverse events and nonserious medical events of special interest were identified by search in the Medical Dic-
tionary for Regulatory Activities, version 18.0. Permanent discontinuation of the treatment regimen was indicated by the 
investigator in the adverse-event form. P values were calculated by means of Pearson’s chi-square test.
†  Confirmed hypoglycemia was defined a plasma glucose level of less than 56 mg per deciliter (3.1 mmol per liter). 
Severe hypoglycemia was defined as hypoglycemia for which the patient required assistance from a third party.
‡  Increased lipase levels were those that were reported by the investigator as adverse events.
§  Events of pancreatitis and neoplasms were adjudicated by the event-adjudication committee. This committee interpret-
ed neoplastic growth as clonal disorders that grow in an autonomous manner. The abnormality of clonal disorder may 
not always have been identified nor could autonomous growth always be determined, but both were considered to be 
fundamental aspects of neoplastic growth.
Table 2. Selected Adverse Events Reported during the Trial.*
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direct effects of liraglutide on kidney func-
tion.21,22
More patients in the liraglutide group than in 
the placebo group permanently discontinued the 
trial regimen owing to adverse events (difference, 
2.2 percentage points). There has been consider-
able interest in a potential association between 
the use of GLP-1–receptor agonists and pancre-
atitis and pancreatic cancer, although there is 
no consistent preclinical, pharmacovigilance, or 
epidemiologic evidence to date.23-25 Higher levels 
of lipase and amylase were observed in the lira-
glutide group, a finding that is similar to results 
in other studies.24 Blinded medications were to 
be stopped only in relation to confirmed pancre-
atitis as evaluated by the investigator. There were 
1.5 episodes of pancreatitis per 1000 patient-
years of observation in both regimens com-
bined, and there were numerically fewer acute or 
chronic pancreatitis events with liraglutide than 
with placebo. There were more episodes of gall-
stone disease with liraglutide, a finding that has 
been reported previously.26
An excess in adjudicated cancers of pancre-
atic origin was observed in the liraglutide group, 
although the finding was not significant; there 
were small overall numbers and no between-
group difference in the number of overall can-
cers. Among rodents receiving liraglutide, high-
er rates of thyroid C-cell tumors and hyperplasia 
have been observed than were observed among 
control animals.27 In the present trial, no epi-
sodes of C-cell hyperplasia or medullary thyroid 
carcinoma were observed in patients in the lira-
glutide group. Randomized trials of this type, 
despite their size, are not powered to determine 
the effect of drugs on cancer risk and can there-
fore neither confirm nor exclude such a possi-
bility.
Many patients in each group were treated 
with sulfonylureas or insulin at baseline, but 
fewer patients in the liraglutide group than in 
the placebo group added insulin during the trial. 
There was a 31% lower rate of severe hypoglyce-
mia and a 20% lower rate of the combination of 
severe and confirmed hypoglycemia (plasma glu-
cose level, <56 mg per deciliter) in the liraglutide 
group than in the placebo group.
A limitation of our trial is that patients were 
followed for only 3.5 to 5.0 years, so the safety 
and efficacy data are restricted to that time pe-
riod. Also, because our trial recruited a popula-
tion of patients who were at high risk for cardio-
vascular events and who had a baseline glycated 
hemoglobin level of 7% or more, the observed 
benefits and risks may not apply to patients at 
lower risk. Furthermore, no adjustments were 
made for multiplicity of exploratory outcomes.
In conclusion, among patients with type 2 
diabetes who were at high risk for cardiovascu-
lar events while they were taking standard 
therapy, those in the liraglutide group had lower 
rates of cardiovascular events and death from 
any cause than did those in the placebo group.
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